Prelude Therapeutics (PRLD) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Surrozen (SRZN) over the past year, gaining 166.0% versus a gain of 82.9%. Over five years, SRZN leads with a -73.5% price change compared with -76.4% for PRLD. Surrozen is the larger company by market cap ($328.7 million vs $309.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRLD | SRZN |
|---|---|---|
| Share price | $3.88 | $27.97 |
| Market cap | $309.64M | $328.75M |
| 1-day change | +1.31% | +11.23% |
| YTD return | +32.07% | +11.26% |
| 1-year return | +165.97% | +82.87% |
| 5-year return | -76.45% | -73.48% |
| EPS (TTM) | $-0.73 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.83 | $37.83 |
| 52-week low | $1.15 | $11.39 |
| Distance from 52-week high | -43.19% | -26.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +137.11% | +73.04% |
| Average volume | 477.45K | 475.02K |
| Shares outstanding | 65.08M | 11.75M |
| Employees | 79 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed SRZN by 83.1 percentage points over the past year.
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
PRLD vs SRZN FAQ
Which is bigger, Prelude Therapeutics or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $328.75M compared with $309.64M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, PRLD or SRZN?
PRLD returned +165.97% over the past 12 months, compared with +82.87% for SRZN (price return, excluding dividends). Past performance does not predict future results.
Are Prelude Therapeutics and Surrozen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Prelude Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Surrozen.